ArticleFrontiers in cell and developmental biology2016
Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice.
Article in Frontiers in cell and developmental biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024Review
- The roles of patient-derived xenograft models and artificial intelligence toward precision medicine.MedComm · 2024Review
- Progress, implications, and challenges in using humanized immune system mice in CAR-T therapy-Application evaluation and improvement.Animal models and experimental medicine · 2024Review
- Organoid co-culture models of the tumor microenvironment promote precision medicine.Cancer innovation · 2024Review
- Editorial: Patient-derived tumor models for drug development.Frontiers in oncology · 2023Article
- Head and neck cancer organoids as a promising tool for personalized cancer therapy: A literature review.Health science reports · 2022Review
- Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer.Oncology letters · 2022Article
- Article
- Novel bone microenvironment model of castration-resistant prostate cancer with chitosan fiber matrix and osteoblasts.Oncology letters · 2021Article
- Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.Molecular cancer · 2021Review
- Engineering approaches for studying immune-tumor cell interactions and immunotherapy.iScience · 2021Review
- Rapid Processing and Drug Evaluation in Glioblastoma Patient-Derived Organoid Models with 4D Bioprinted Arrays.iScience · 2020Article
- Review
- Epidermal Growth Factor Is Essential for the Maintenance of Novel Prostate Epithelial Cells Isolated From Patient-Derived Organoids.Frontiers in cell and developmental biology · 2020Article
- Organoid models of glioblastoma: advances, applications and challenges.American journal of cancer research · 2020Review
- Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.Translational andrology and urology · 2019Review
- Review
- Addressing Patient Specificity in the Engineering of Tumor Models.Frontiers in bioengineering and biotechnology · 2019Review
- Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.European urology oncology · 2018Article
- Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.Biochimica et biophysica acta. Reviews on cancer · 2018Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer death in Western men. Despite its prevalence, PCa has proven very difficult to propagate in vitro. PCa represents a complex organ-like multicellular structure maintained by the dynamic interaction of tumoral cells with parenchymal stroma, endothelial and immune cells, and components of the extracellular matrix (ECM). The lack of PCa models that recapitulate this intricate system has hampered progress toward understanding disease progression and lackluster therapeutic responses. Tissue slices, monolayer cultures and genetically engineered mouse models (GEMM) fail to mimic the complexities of the PCa microenvironment or reproduce the diverse mechanisms of therapy resistance. Moreover, patient derived xenografts (PDXs) are expensive, time consuming, difficult to establish for prostate cancer, lack immune cell-tumor regulation, and often tumors undergo selective engraftments. Here, we describe an interdisciplinary approach using primary PCa and tumor initiating cells (TICs), three-dimensional (3D) tissue engineering, genetic and morphometric profiling, and humanized mice to generate patient-derived organoids for examining personalized therapeutic responses in vitro and in mice co-engrafted with a human immune system (HIS), employing adaptive T-cell- and chimeric antigen receptor- (CAR) immunotherapy. The development of patient specific therapies targeting the vulnerabilities of cancer, when combined with antiproliferative and immunotherapy approaches could help to achieve the full transformative power of cancer precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.